Baerveldt 250平方毫米青光眼植入物的临床经验。

Clinical experience with the Baerveldt 250-mm2 Glaucoma Implant.

作者信息

WuDunn Darrell, Phan Anh-Danh T, Cantor Louis B, Lind John T, Cortes Arnold, Wu Bin

机构信息

Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA.

出版信息

Ophthalmology. 2006 May;113(5):766-72. doi: 10.1016/j.ophtha.2006.01.049.

DOI:10.1016/j.ophtha.2006.01.049

PMID:16650671

Abstract

PURPOSE

To report the intermediate-term results of the Baerveldt 250-mm2 Glaucoma Implant for treatment of adult glaucoma.

DESIGN

Retrospective, noncomparative, interventional case series.

PARTICIPANTS

One hundred eight adult patients (108 eyes) with glaucoma who received a Baerveldt 250-mm2 Glaucoma Implant.

INTERVENTION

Implantation of the Baerveldt 250-mm2 Glaucoma Implant.

MAIN OUTCOME MEASURES

Intraocular pressure (IOP), visual acuity, number of glaucoma medications, and surgical complications. Success was defined as IOP > or = 6 mmHg and < or = 21 mmHg (with or without antiglaucoma medications), without further glaucoma surgery, devastating complication, or loss of light perception attributable to drainage implantation.

RESULTS

Mean age was 63.8+/-16.5 years. Mean postoperative follow-up was 22.8 months (range, 0.2-84.9; interquartile range, 3.9-36.3). Mean preoperative IOP was 36.3+/-13.0 mmHg, on 2.9+/-1.1 antiglaucoma medications. The mean postoperative IOP at final visit was 15.8+/-7.6 mmHg (P<0.0001, paired t test), on 0.8+/-1.0 antiglaucoma medications (P<0.0001, Wilcoxon test). Kaplan-Meier success rates were 0.92 (6 months, n = 81), 0.88 (12 months, n = 75), 0.84 (18 months, n = 68), and 0.79 (24 months, n = 61).

CONCLUSIONS

The Baerveldt 250-mm2 Glaucoma Implant provides good intermediate-term success for the treatment of adult refractory glaucoma.

摘要

目的

报告Baerveldt 250平方毫米青光眼植入物治疗成人青光眼的中期结果。

设计

回顾性、非对比性、介入性病例系列。

参与者

108例接受Baerveldt 250平方毫米青光眼植入物的成年青光眼患者（108只眼）。

干预措施

植入Baerveldt 250平方毫米青光眼植入物。

主要观察指标

眼压（IOP）、视力、青光眼药物使用数量及手术并发症。成功定义为眼压≥6 mmHg且≤21 mmHg（无论是否使用抗青光眼药物），无需进一步青光眼手术、严重并发症或因引流植入导致光感丧失。

结果

平均年龄为63.8±16.5岁。术后平均随访时间为22.8个月（范围0.2 - 84.9个月；四分位间距3.9 - 36.3个月）。术前平均眼压为36.3±13.0 mmHg，使用2.9±1.1种抗青光眼药物。末次随访时术后平均眼压为15.8±7.6 mmHg（配对t检验，P<0.0001），使用0.8±1.0种抗青光眼药物（Wilcoxon检验，P<0.0001）。Kaplan-Meier成功率在6个月时为0.92（n = 81），12个月时为0.88（n = 75），18个月时为0.84（n = 68），24个月时为0.79（n = 61）。